V. A. Miller

2.2k total citations · 1 hit paper
37 papers, 1.5k citations indexed

About

V. A. Miller is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, V. A. Miller has authored 37 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Pulmonary and Respiratory Medicine, 29 papers in Oncology and 7 papers in Cancer Research. Recurrent topics in V. A. Miller's work include Lung Cancer Treatments and Mutations (30 papers), Lung Cancer Diagnosis and Treatment (13 papers) and Lung Cancer Research Studies (13 papers). V. A. Miller is often cited by papers focused on Lung Cancer Treatments and Mutations (30 papers), Lung Cancer Diagnosis and Treatment (13 papers) and Lung Cancer Research Studies (13 papers). V. A. Miller collaborates with scholars based in United States, United Kingdom and Taiwan. V. A. Miller's co-authors include Mark G. Kris, Eric K. Rowinsky, Lisa A. Hammond, A. Feyereislova, Andrew B. Tullo, Malcolm Ranson, Charles Morris, Philip I. Murray, D. K. Ferry and Helen Swaisland and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

V. A. Miller

36 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

2002 646 citations Mark G. Kris, V. A. Miller et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
V. A. Miller United States	18	1.2k	1.0k	529	195	132	37	1.5k
Thanyanan Reungwetwattana Thailand	21	1.1k 1.0×	1.4k 1.3×	571 1.1×	321 1.6×	138 1.0×	72	1.9k
Georgiana Kuhlmann United States	5	753 0.6×	920 0.9×	500 0.9×	357 1.8×	109 0.8×	6	1.3k
Ira A. Oliff United States	8	1.3k 1.1×	1.2k 1.2×	451 0.9×	226 1.2×	61 0.5×	12	1.7k
Erzsébet Juhász Hungary	15	1.2k 1.0×	1.1k 1.0×	568 1.1×	235 1.2×	93 0.7×	28	1.7k
Nicholas A. Jessop United States	6	843 0.7×	959 0.9×	676 1.3×	289 1.5×	211 1.6×	9	1.3k
Chiara Lazzari Italy	24	883 0.7×	738 0.7×	580 1.1×	313 1.6×	103 0.8×	67	1.5k
H. Spiridonidis United States	4	1.7k 1.4×	1.8k 1.7×	541 1.0×	288 1.5×	76 0.6×	8	2.1k
Paul Conkling United States	22	1.2k 1.0×	656 0.6×	523 1.0×	140 0.7×	80 0.6×	97	1.7k
Roberta Caputo Italy	13	805 0.7×	664 0.6×	612 1.2×	317 1.6×	94 0.7×	27	1.4k

Countries citing papers authored by V. A. Miller

Since Specialization

Citations

This map shows the geographic impact of V. A. Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V. A. Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V. A. Miller more than expected).

Fields of papers citing papers by V. A. Miller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V. A. Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V. A. Miller. The network helps show where V. A. Miller may publish in the future.

Co-authorship network of co-authors of V. A. Miller

This figure shows the co-authorship network connecting the top 25 collaborators of V. A. Miller. A scholar is included among the top collaborators of V. A. Miller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V. A. Miller. V. A. Miller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Serebriiskii, Ilya G., Caitlin Connelly, Garrett M. Frampton, et al.. (2019). Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients. Nature Communications. 10(1). 3722–3722. 149 indexed citations

Halmos, Balázs, Garrett M. Frampton, James Suh, et al.. (2016). Lung sarcomatoid carcinoma (LSC) harbors targetable genomic alterations and high mutational burden as observed by comprehensive genomic profiling (CGP). Annals of Oncology. 27. vi419–vi419. 2 indexed citations

Ali, Siraj M., Matthew Hawryluk, Kai Wang, et al.. (2014). Abstract A28: Clinical next-generation sequencing (NGS) reveals genomic alterations (GAs) to guide targeted therapy in advanced neuroblastoma patients. Cancer Research. 74(20_Supplement). A28–A28. 1 indexed citations

Hirsh, Vera, J. Cadranel, Xiuyu Julie Cong, et al.. (2013). Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results of a Randomized Phase IIb/III Trial (LUX-Lung 1). Journal of Thoracic Oncology. 8(2). 229–237. 61 indexed citations

Paik, Paul K., et al.. (2011). Response to EGFR TKIs in never smokers with stage IV EGFR mutant squamous cell carcinoma of the lung (SQCC).. Journal of Clinical Oncology. 29(15_suppl). e18020–e18020. 1 indexed citations

Rekhtman, Natasha, Paul K. Paik, Maria E. Arcila, et al.. (2011). Screening for EGFR, KRAS, and PIK3CA mutations in well-characterized, immunohistochemically confirmed squamous cell carcinoma of lung.. Journal of Clinical Oncology. 29(15_suppl). e21143–e21143. 1 indexed citations

Janjigian, Y. Y., Harry J.M. Groen, Leora Horn, et al.. (2011). Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib.. Journal of Clinical Oncology. 29(15_suppl). 7525–7525. 121 indexed citations

D’Angelo, Sandra P., Paul K. Paik, Gregory J. Riely, et al.. (2010). EGFR mutations in men and cigarette smokers with lung adenocarcinoma.. Journal of Clinical Oncology. 28(15_suppl). 10538–10538. 4 indexed citations

Shih, Jin‐Yuan, James Chih‐Hsin Yang, Wei‐Juin Su, et al.. (2009). A phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of one line of chemotherapy (LUX-Lung 2). Journal of Clinical Oncology. 27(15_suppl). 8013–8013. 21 indexed citations

10.

Miller, V. A., Paula G. O’Connor, C. Soh, & Fairooz F. Kabbinavar. (2009). A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 27(18_suppl). LBA8002–LBA8002. 54 indexed citations

11.

Miller, V. A., Heather A. Wakelee, Primo N. Lara, et al.. (2008). Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: Preliminary results of a phase II trial. Journal of Clinical Oncology. 26(15_suppl). 8028–8028. 30 indexed citations

12.

Jackman, D. M., Lecia V. Sequist, Leigh‐Anne Cioffredi, et al.. (2008). Impact of EGFR and KRAS genotype on outcomes in a clinical trial registry of NSCLC patients initially treated with erlotinib or gefitinib. Journal of Clinical Oncology. 26(15_suppl). 8035–8035. 11 indexed citations

13.

Rizvi, Naiyer A., Mark G. Kris, V. A. Miller, et al.. (2008). Activity of XL647 in clinically selected NSCLC patients (pts) enriched for the presence of EGFR mutations: Results from Phase 2. Journal of Clinical Oncology. 26(15_suppl). 8053–8053. 23 indexed citations

14.

Miller, V. A., Gregory J. Riely, William Pao, et al.. (2006). EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC): Results of a prospective phase II trial. Journal of Clinical Oncology. 24(18_suppl). 7003–7003. 37 indexed citations

15.

Riely, Gregory J., et al.. (2005). Clinical characteristics and natural history of patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations treated with erlotinib or gefitinib. Journal of Clinical Oncology. 23(16_suppl). 7085–7085. 2 indexed citations

16.

Kris, Mark G., V. A. Miller, William Pao, et al.. (2005). EGFR and KRAS mutations in patients with bronchioloalveolar carcinoma treated with erlotinib in a phase II multicenter trial. Journal of Clinical Oncology. 23(16_suppl). 7029–7029. 21 indexed citations

17.

Krug, Lee M., V. A. Miller, Gregory P. Kalemkerian, et al.. (2000). Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer. Annals of Oncology. 11(2). 227–228. 53 indexed citations

18.

Miller, V. A. & Mark G. Kris. (2000). Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer.. PubMed. 27(2 Suppl 3). 3–10. 20 indexed citations

19.

Krug, Lee M. & V. A. Miller. (1999). Phase II trials of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer.. PubMed. 26(5 Suppl 16). 24–6; discussion 41. 7 indexed citations

20.

Miller, V. A., Kenneth Ng, Stefan C. Grant, et al.. (1997). Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. Annals of Oncology. 8(12). 1269–1271. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact